Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Adults
Ligand to Participate in Upcoming Investor Conferences
Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement
Ligand Reports First Quarter 2024 Financial Results
Ligand to Report First Quarter 2024 Financial Results on May 7, 2024
Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference
Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™
Ligand to Present at Barclays 26th Annual Global Healthcare Conference
Ligand Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results